Online survey for patients affected by non-tuberculous mycobacterial lung disease (NTM-LD) in Europe


European NTM lung disease Patient Disease Experience survey

Thank You

Dear visitor,


Thank you for your interest in the ENPADE survey. The ENPADE survey was a combination of an anonymous online survey and a number of pseudonymized interviews among people affected by non-tuberculous mycobacterical lung disease (NTM-LD). 


NTM-LD is a bacterial infection caused by non-tuberculous mycobacteria for which treatment typically requires taking multiple antibiotics, often for several years. NTM-LD is a rare lung disease. It particularly affects already vulnerable patients with chronic lung conditions like COPD, bronchiectasis, cystic fibrosis, or patients with an impaired immune system.


The ENPADE survey has helped to better understand patient’s experience of care and burden of disease. The results are expected to help to improve healthcare for NTM-LD patients in Europe.


The survey was successfully completed at the end of February 2022 and has since been evaluated. A short summary of the results can be found below.


Supported by

Sponsored by

If you have any further questions, please do not hesitate to send us an e-mail on